expert-interview
Overcoming the Challenges in Bioanalysis of Oligonucleotide-based Therapies and Relevance to the Clinical Development Plan. “Gene therapy provides the hope of actual cures. These therapies still have many challenges to overcome before they will become widely developed therapeutic options.” This interview features Frontage's Chief Business Officer, Hugh Davis, and Vice President of Biologics Services, Weiping Shao.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.